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The ImpacT of emeRgIng maRkeTS on The 
phaRmaceuTIcal InduSTRy
M. Tannoury; and Z. Attieh
American University of Science and Technology, Beirut, Lebanon
Emerging markets are considered nowadays the “Promised Land” 
for pharmaceutical industries. Although a clear-cut definition of 
these markets is not yet available, Forbes magazine along with 
other economists define them as developing prosperous countries. 
In these countries, an investment is expected to result in higher 
income despite the high risks. Qualifying a market as emerging is 
not solely based on the country’s economic status but rather on a 
series of criteria making the definition relative to each. Jim O’Neill, 
retired chairman of Goldman Sachs Asset Management, coined 
the names of the 2 leading economies of emerging markets into 
2 acronyms. BRICS countries (Brazil, Russia, India, China, and 
later South Africa) emerged first and were followed years later by 
MIST countries (Mexico, Indonesia, South Korea, and Turkey) as 
the second wave of tiers countries joining emerging markets. In the 
last 5 years, sales of pharmaceuticals in BRICS and MIST mar-
kets doubled, reaching a share of ~20% globally. This shift stems 
from the huge populations of the concerned societies, an increasing 
prosperity, and life expectancy. In addition, companies are suffering 
from a flattened growth rate in developed markets, the expiration 
of > 40% of patents leading to the up-selling of cheaper generic 
drugs, and the existing tight regulations. However, Big Pharma needs 
to be cautioned regarding these emerging markets. Pharmaceutical 
companies wanting to expand in these emerging opportunities have 
to tailor their strategies according to the developing pace of each 
country. These communities are in need of drugs against infectious 
and communicable diseases such as sexually transmitted diseases. 
They are ready-to-exploit territories for the innovative products of 
pharmaceuticals. However, with the increase in wealth and longevity, 
a change of lifestyle is slowly taking place accompanied by a shift in 
the disease trends. A disproportionately fast rise in the incidence of 
noncommunicable diseases such as cardiovascular illnesses, diabetes, 
and cancers is noticed in emerging markets, mimicking the pattern of 
their Western counterparts. The incidence of diabetes and oncologic 
diseases is expected to grow by ≥ 20% in the next 5 years. This could 
be viewed as a mixed blessing, as pharmaceutical industries will 
be able to sell their global products in these new markets as well. 
Industries face challenges to conquer emerging markets grouped 
into 3 categories: infrastructure development, cost-containment poli-
cies, and value-driven drug evaluation. To overcome these hurdles, 
new strategies need to be adopted by pharmaceutical companies. 
Adequate tailoring and gain in market are among the top strategies 
to be considered.
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Background: In hospitals, clinical data are often scattered across 
multiple databases and application systems due to decentralized clini-
cal information system architectures. Consequently, the reuse of once 
collected data for secondary purposes as data analytics and data 
mining is considered a challenging task.1 Enterprise Data Warehouses 
(EDW) have been established at several medical centers to overcome 
typical obstacles to data reuse such as proprietary data models, ter-
minologies, lack of governance, and more. However, the complexity 
and high rate of change of the clinical domain and medical data 
cause high costs for maintenance of data models and the provision 
of data to researchers.2 Detailed Clinical Models might help to better 
manage these domain-specific challenges by introducing formal and 
computable methods to represent clinical content models to data 
warehousing.3 One example of a Detailed Clinical Model approach 
is openEHR, a specification of an open, interoperable electronic 
health record.4 Although the use of openEHR in the context of a 
health information exchange is well established, there is still a lack 
of evidence regarding its feasibility to represent and integrate legacy 
data into EDWs.
Methods: We chose the domain of intensive care medicine to investi-
gate if openEHR can meet a diverse set of requirements to represent 
and help integrate clinical data that are stored in application systems. 
At Hannover Medical School, 2 independent patient data manage-
ment systems (COPRA and m.life) are incorporated at the intensive 
care wards. We identified a test set of 8 clinical concepts that are 
commonly used in these systems: blood pressure, body temperature, 
pulse, heart rate, indirect oximetry, Braden Scale, Glasgow Coma 
Scale, and ventilation. For each of these measurements, we intended 
to obtain an openEHR Archetype (a formal content model of a clini-
cal concept) or to create a new one. Subsequently, Archetypes were 
used to create a Template, which can be thought of as a use case-
specific document. For the task of data integration and mapping, we 
used a combination of Microsoft SSIS, Altova MapForce 2014, and 
the Template Document Schema approach.5
Results: We obtained 7 Archetypes from the Clinical Knowledge 
Manager, the public content model repository of the openEHR 
Foundation. Because no ventilation Archetype was available at the 
time of this work, we created a new Archetype. We found it possible 
to map most types of legacy data from the given application systems 
to openEHR Templates. The representation and mapping of Braden 
Scales and Glasgow Coma Scales data were straightforward. By con-
trast, the mapping of continuous sensor data (eg, blood pressure 
measurements generated by sensors) required the arbitrary segmenta-
tion of values into multiple documents. For this purpose, we chose 
a 24-hour interval. When integrating ventilation data, we found a 
high number of corresponding variables in the source systems (~300). 
Because available resources were limited, we decided to create a first 
draft version of the ventilation Archetype that only represents data 
elements of the most important parameters. In coordination with a 
clinical expert, 30 data items were identified and then modeled in 
the archetype.
